Skin Care Supports Systemic Health: How Treating Skin Disease May Reduce Cardiovascular, Metabolic, and Cognitive Risk
A comprehensive review reveals that treating skin disorders and using daily emollients reduces cardiovascular risk, depression, cognitive decline, and metabolic disease.
Summary
This perspective review synthesizes evidence showing that the skin is far more than a barrier — it is an active regulator of systemic health. Skin disorders like psoriasis and atopic dermatitis raise risks of type 2 diabetes, cardiovascular disease, obesity, and depression. Critically, treating these skin conditions meaningfully reduces those systemic risks. Beyond disease treatment, daily topical emollient use in elderly populations lowered circulating pro-inflammatory cytokines and slowed progression of mild cognitive impairment. In preterm neonates, emollient application reduced mortality. The paper argues that maintaining healthy skin — via both medical treatment and routine skincare — should be considered a component of holistic disease prevention and healthy aging strategy.
Detailed Summary
This 2025 perspective review from Chinese dermatologists, drawing on PubMed and Google Scholar literature through March 2025, synthesizes a large and compelling body of evidence establishing bidirectional links between skin health and systemic disease. The central argument is that the skin — while not the body's largest organ by weight — is uniquely exposed to environmental stressors and actively communicates with the immune, endocrine, and nervous systems in ways that profoundly shape overall health. When skin barrier function deteriorates, whether from aging, inflammatory disease, or environmental insult, the consequences extend well beyond the dermis.
Psychological health is one of the most robustly documented domains. Depression prevalence is 20.1% in individuals with atopic dermatitis versus 14.8% in controls. Psoriasis raises depression risk with an adjusted odds ratio of 1.30 (p=0.045), and psoriasis severity (PASI score) correlates positively with Beck Depression Inventory scores. Treatment with biologics such as dupilumab, adalimumab, and secukinumab dramatically reduces both skin severity and depression/anxiety scores. A study in 7,490 psoriatic patients found that biologic therapy produced a depression incidence rate of 3.01 (95% CI: 2.73–3.32) versus 5.85 for phototherapy. Among biologics, adalimumab showed the strongest protective effect (hazard ratio for depression = 0.63, 95% CI: 0.46–0.86 vs. conventional therapy).
For type 2 diabetes, inflammatory skin disease drives measurable metabolic harm. Psoriasis independently increases diabetes risk, with severity tracked by body surface area involvement. A retrospective cohort study found that dupilumab treatment in atopic dermatitis patients reduced type 2 diabetes incidence with a hazard ratio of 0.53 (95% CI: 0.42–0.68; p<0.001). Topical betamethasone or tacrolimus for two weeks also improved insulin resistance, likely by reducing cutaneous inflammation rather than a direct glycemic effect. Obesity links are similarly bidirectional: moderate-to-severe atopic dermatitis patients face a 20-fold greater odds of obesity versus mild atopic dermatitis (OR 20.4, 95% CI 6.53–90.7). Treating psoriasis with oral roflumilast achieved weight loss in 53.4% of responders, including an 8% BMI reduction in women at week 48 (p<0.001).
Cardiovascular risk reduction from skin disease treatment is striking. TNF inhibitor therapy in psoriasis patients reduced myocardial infarction risk with an adjusted hazard ratio of 0.50 (95% CI: 0.32–0.79 vs. topical treatment). Biologic therapy also improved diastolic function (E/e' ratio declining from 8.1±2.1 to 6.7±1.9, p<0.001) and global longitudinal strain (from -16.8±2.1 to -18.3±2.3%, p<0.001).
For aging specifically, the mechanism linking skin to systemic inflammation is central. Aged skin shows elevated pH, reduced stratum corneum hydration, and delayed barrier recovery — all drivers of cutaneous inflammation and elevated circulating pro-inflammatory cytokines. Applying a simple topical emollient in elderly subjects lowered those cytokines and, in one clinical trial, prevented progression of mild cognitive impairment. In autism spectrum disorder, elevated IL-17A in both skin and brain was attenuated by emollient application in children. The implications are clear: routine skin care in older adults may constitute a genuinely accessible anti-inflammaging strategy with measurable cognitive and metabolic benefits.
Key Findings
- Depression prevalence was 20.1% in individuals with atopic dermatitis versus 14.8% in those without (source-cited figure)
- Psoriasis independently increased depression risk with an adjusted odds ratio of 1.30 (p=0.045), and PASI severity correlated positively with Beck Depression Inventory scores
- Dupilumab treatment for atopic dermatitis reduced type 2 diabetes incidence with hazard ratio 0.53 (95% CI: 0.42–0.68; p<0.001) in a retrospective cohort study
- TNF inhibitor therapy in psoriasis patients reduced myocardial infarction risk with adjusted hazard ratio 0.50 (95% CI: 0.32–0.79) versus topical treatment
- Moderate-to-severe atopic dermatitis patients had roughly 20-fold higher obesity odds versus those with mild disease (OR 20.4, 95% CI: 6.53–90.7)
- Oral roflumilast for psoriasis produced weight loss in 53.4% of responders, with women showing ~8% BMI reduction at week 48
- Topical emollient application in elderly subjects lowered circulating pro-inflammatory cytokines and, in one clinical trial, prevented progression of mild cognitive impairment
Methodology
This is a narrative perspective review, not a primary study. Authors systematically searched PubMed and Google Scholar from inception through March 2025, synthesizing observational studies, retrospective cohorts, randomized controlled trials, and animal model data. No formal meta-analytic pooling or PRISMA methodology was applied. Evidence quality varies substantially across cited studies, ranging from large cohort data (n=7,490 for one psoriasis trial) to small-scale clinical studies and mouse model experiments.
Study Limitations
As a narrative perspective review rather than a systematic review or meta-analysis, this paper is subject to publication bias and selective citation; no formal risk-of-bias assessment or PRISMA-style grading was performed. Causal directionality between skin disease and systemic conditions remains largely unresolved, as most cited studies are observational or retrospective. Only the article's front matter and introduction were available for verification; specific numerical claims in downstream sections (biologic-specific hazard ratios, roflumilast weight-loss percentages, cardiac strain metrics) originate from the review's cited primary studies and could not be independently reverified against the full text in this review pass. Funding was provided by the Suzhou Municipal Science and Technology Bureau; authors declare no explicit conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: